Founding investor Mercia Technologies joined fund manager Invesco for the synthetic biology contractor’s latest round, taking its total funding past the $25m mark.
Oxford Genetics, a UK-based synthetic biology services provider founded by a former University of Oxford scientist, has secured £6.5m ($8.5m) in funding at a post-money valuation of approximately $40m.
The round included Mercia Technologies, the research-focused investment firm Mercia Technologies that is also Oxford Genetics’ founding investor, as well as fund manager Invesco Asset Management and financial services firm Canaccord Genuity.
Mercia contributed $520,000 to the round but its stake was diluted from 40.5% to approximately 33%. It…
